Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iB ...

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in January. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-dig ...

Core Viewpoint - iBio, Inc. reported significant progress in its financial position and pipeline development during the third quarter of fiscal 2025, including a successful equity raise and promising data for its lead therapeutic candidates [2][4]. Financial Results - For the third quarter ended March 31, 2025, iBio reported R&D expenses of approximately $1.9 million, an increase of about $1.0 million compared to $0.9 million in the same period of 2024, primarily due to higher spending on consultants, supplies, and personnel [7]. - General and administrative (G&A) expenses for the same period were approximately $3.0 million, up from $2.7 million in 2024, with the increase attributed to IT costs, consulting fees, and franchise taxes [7]. - The net loss from continuing operations for the third quarter was approximately $4.9 million, or $0.49 per share, compared to a net loss of approximately $2.6 million, or $0.71 per share, in the same period of fiscal 2024 [7]. - As of March 31, 2025, cash, cash equivalents, and restricted cash totaled approximately $5.2 million, which increased to approximately $10.5 million following a warrant inducement transaction in April 2025 [7]. Corporate Updates - iBio successfully transitioned to trading on the Nasdaq Stock Exchange under the ticker symbol "IBIO," enhancing visibility and liquidity, and aligning with its strategy to attract long-term institutional investors [7]. - The company reported promising non-human primate data for IBIO-600, a long-acting anti-myostatin antibody, indicating extended half-life and dose-dependent muscle growth [7]. - iBio in-licensed a first-in-class Activin E antibody from AstralBio, expanding its pipeline focused on cardiometabolic diseases and obesity [7]. - The company raised $6.2 million in gross proceeds through a warrant inducement transaction, strengthening its balance sheet and providing additional working capital for pipeline advancements [7].

Core Insights - iBio, Inc. has announced promising pharmacokinetics data for IBIO-600, a long-acting anti-myostatin antibody, suggesting a potential human half-life of up to 130 days, which could position it as a best-in-class treatment for muscle preservation and weight loss [1][4][5] - The company is on track to submit a regulatory application for IBIO-600 in Q1 2026, highlighting its commitment to innovation in obesity treatment [1][5] Group 1: IBIO-600 Development - The pharmacokinetics study involved non-human primates (NHPs) and indicated a half-life of 40 to 52 days in NHPs, with human estimates ranging from 57 to 130 days [4] - The study demonstrated a dose-dependent increase in lean mass and a reduction in fat mass, with the low-dose group showing a 3.1% increase in lean mass and the high-dose group a 5.1% increase after 8 weeks [3] - The potential for a dosing schedule of once every 3 to 6 months could significantly reduce the treatment burden for patients [4][5] Group 2: Activin E Antibody - iBio has also disclosed preclinical data for a first-in-class Activin E antibody, which effectively blocks Activin E signaling and shows promise as a novel obesity treatment [5] - In an exploratory study with obese mice, the Activin E antibody as a monotherapy resulted in a 4% fat-selective weight loss and an 18% reduction in total body fat compared to placebo [5] - When combined with semaglutide, the Activin E antibody enhanced total weight loss by an additional 9%, leading to an overall weight reduction of 34% and a 72% reduction in body fat [5]